FDA Warns Gilead, Biogen Over Drug Ads

Law360, New York (April 7, 2010, 6:15 PM EDT) -- The U.S. Food and Drug Administration has put drugmakers Gilead Sciences Inc. and Biogen Idec Inc. on alert over their distribution of allegedly false and misleading advertisements for their products.

The FDA on Wednesday released two separate letters issued to the companies on March 25 that warned Gilead over a direct-to-consumer print advertisement for its HIV drug Truvada and cautioned Biogen over a promotional webcast publicizing multiple sclerosis treatment Tysabri.

Gilead, a biopharmacuetical company that develops and commercializes treatments for viral and infectious diseases, has been...
To view the full article, register now.